CC
Casdin Capital Portfolio holdings
AUM $1.1B
1-Year Return
24.98%
This Quarter Return
+38.67%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$170M
AUM Growth
+$48.4M
(+40%)
Cap. Flow
+$2.8M
Cap. Flow
% of AUM
1.65%
Top 10 Holdings %
Top 10 Hldgs %
66.82%
Holding
34
New
9
Increased
8
Reduced
9
Closed
5
Top Buys
| 1 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$4.43M |
| 2 |
Sangamo Therapeutics
SGMO
|
+$4.42M |
| 3 |
Pacific Biosciences
PACB
|
+$3.62M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
+$3.6M |
| 5 |
Codexis
CDXS
|
+$3.24M |
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$7.46M |
| 2 |
BLUE
bluebird bio
BLUE
|
+$5.18M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
+$4.04M |
| 4 |
Illumina
ILMN
|
+$3.2M |
| 5 |
CERN
Cerner Corp
CERN
|
+$3.08M |
Sector Composition
| 1 | Healthcare | 88.88% |
| 2 | Materials | 1.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
1
DELISTED
Sage Therapeutics
SAGE
| $18.1M | 10.69% |
255,000
-4,500
| -2% | -$320K |
|
|
FMI
2
DELISTED
Foundation Medicine, Inc.
FMI
| $15.5M | 9.13% |
480,000
-66,000
| -12% | -$2.13M |
|
|
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
| $15.1M | 8.94% |
360,000
| – | – |
|
4
Agios Pharmaceuticals
AGIO
$2.11B
| $13.9M | 8.18% |
237,500
-3,000
| -1% | -$175K |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $11.8M | 6.95% |
294,500
+50,000
| +20% | +$2M |
|
6
Evolent Health
EVH
$994M
| $11.6M | 6.84% |
520,000
-35,000
| -6% | -$781K |
|
|
EPZM
7
DELISTED
Epizyme, Inc
EPZM
| $8.32M | 4.91% |
485,000
+210,000
| +76% | +$3.6M |
|
|
ONCE
8
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $7.2M | 4.25% |
135,000
+6,500
| +5% | +$347K |
|
9
Voyager Therapeutics
VYGR
$237M
| $6.62M | 3.91% |
500,000
+115,000
| +30% | +$1.52M |
|
|
GNMK
10
DELISTED
GenMark Diagnostics, Inc
GNMK
| $5.13M | 3.03% |
400,000
-110,000
| -22% | -$1.41M |
|
|
BOLD
11
DELISTED
Audentes Therapeutics, Inc
BOLD
| $4.43M | 2.61% |
+260,000
| New | +$4.43M |
|
|
12
Sangamo Therapeutics
SGMO
$154M
| $4.42M | 2.61% |
+850,000
| New | +$4.42M |
|
|
MDRX
13
DELISTED
Veradigm Inc. Common Stock
MDRX
| $3.93M | 2.32% |
310,000
+30,000
| +11% | +$380K |
|
|
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.74M | 2.21% |
101,500
-202,500
| -67% | -$7.46M |
|
|
15
Pacific Biosciences
PACB
$354M
| $3.62M | 2.14% |
+700,000
| New | +$3.62M |
|
|
MYOK
16
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $3.49M | 2.06% |
265,000
| – | – |
|
|
KITE
17
DELISTED
Kite Pharma, Inc.
KITE
| $3.34M | 1.97% |
42,500
-51,500
| -55% | -$4.04M |
|
|
18
Codexis
CDXS
$218M
| $3.24M | 1.91% |
+675,000
| New | +$3.24M |
|
|
AMRS
19
DELISTED
Amyris Inc.
AMRS
| $3.18M | 1.88% |
400,000
+171,667
| +75% | +$1.36M |
|
20
CytomX Therapeutics
CTMX
$323M
| $3.07M | 1.81% |
177,500
+50,000
| +39% | +$863K |
|
21
Editas Medicine
EDIT
$228M
| $2.98M | 1.76% |
133,333
+68,333
| +105% | +$1.53M |
|
|
SYRS
22
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $2.9M | 1.71% |
18,214
| – | – |
|
|
JNCE
23
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.86M | 1.69% |
+130,000
| New | +$2.86M |
|
24
Alnylam Pharmaceuticals
ALNY
$60.7B
| $2.82M | 1.66% |
55,000
-30,000
| -35% | -$1.54M |
|
|
TSRO
25
DELISTED
TESARO, Inc.
TSRO
| $2.69M | 1.59% |
+17,500
| New | +$2.69M |
|